De novo judicial review describes a review of a trial court’s decision by a court of appeals and is used in questions of how ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...

When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...

Novo Nordisk remains a Strong Buy despite recent earnings misses, trial setbacks, and competitive pressures in the weight loss/diabetes market. NVO's valuation is compelling, trading at a low P/E of ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease. Novo ...

Novo Nordisk said on Monday an older oral version of its semaglutide drug failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer’s ...

The studies were a setback for the optimistic view that semaglutide and other drugs used in obesity and diabetes treatment could help prevent a number of brain diseases. By Gina Kolata Gina Kolata has ...

Upcoming data from Novo Nordisk A/S (NYSE: NVO) early next month could offer the clearest signal yet on whether GLP-1 medicines — widely used for diabetes and weight loss — can also slow the ...

Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the US market ...

Novo Nordisk is cutting the out-of-pocket prices of its popular weight-loss drug Wegovy and diabetes drug Ozempic for some consumers. Current customers who pay for the drugs out of pocket — without ...

Novo Holdings sells 155 million Convatec shares at 5.1% discount Sale marks Novo's exit from Convatec Convatec shares fall as much as 4.3% Shares in Convatec fell as much as 4.3% to 228.8 pence per ...